The Alliance for mRNA Medicines (AMM) is the leading global organization dedicated to advancing and advocating for mRNA and next-generation encoding RNA therapeutics and vaccines for the benefit of patients, public health, and society. Our mission is to propel the future of mRNA medicine, improve patients’ lives, and advance scientific knowledge by convening and empowering mRNA industry leaders, innovators, scientists, and other key stakeholders.
Board Chair
Replicate Bioscience
Board Vice-Chair
CSL
Board Treasurer
Project Farma and Precision ADVANCE
Board Secretary
Maravai Life Sciences
At-Large Board Executive
Danaher
At-Large Board Executive
BioNTech
Acuitas Therapeutics
Akron Biotech
Arcturus Therapeutics
Australian National University
BASE mRNA Facility, The University Of Queensland
BioNTech
CSL
Curapath
CureVac
Cytonus
Danaher
Danaher
De novo
Eclipse BioInnovations
etherna
Ethris
Exothera
ExploRNA Therapeutics
Genevant Sciences
Genvax
Ginkgo Bioworks
HDT Bio Corp.
IPSS
Johns Hopkins
Maravai LifeSciences
MaxCyte
Mayo Clinic
Mercury Bio
MJH Life Sciences
Nutcracker
Parcel Biosciences, Inc.
Primrose Bio
Project Farma
Providence
Quantoom
ReciBioPharm
ReCode Therapeutics
Replicate Bioscience
Sail Biomedicines
Texas A&M National Center for Therapeutics Manufacturing
Vernal
Verve
Whywevax
Ziphius Vaccines
Executive Director
Managing Director
Senior Advisor
AMM members represent some of the most recognized mRNA innovators in the field. Bringing the best minds together, we aim to overcome the most critical obstacles inhibiting the advancement of mRNA research, development and manufacturing.
Interested in becoming a member of AMM? Check out the benefits of membership below.
Leverage the combined strength of the global mRNA community to define and advance the sector’s top policy priorities before influential legislative leaders in North America, Europe, and Asia.
Accelerate your projects through our proactive engagement with regulatory agencies, working towards the swift approval of new mRNA therapeutics and vaccines. Spearhead global efforts to establish quality manufacturing standards and metrics.
In the rapidly advancing world of mRNA and RNA medicines, AMM members gain exclusive insights into the cutting-edge technology and research driving our sector forward. AMM promotes technological collaborations between our members and leading tech innovators worldwide, and invites members to take part in AMM’s Science and Technology work groups.
Our comprehensive awareness and education program increases understanding of mRNA and next-generation encoding RNA therapeutics and vaccines’ potential. Our global communications strategy educates the marketplace and policy arenas, and offers members timely, relevant, and impactful industry news.
Connect with our community of innovators, therapeutic developers, and key opinion leaders at AMM’s exclusive networking events. From our annual flagship meeting to smaller regional roundtables, you’ll engage with experts and leaders shaping the industry.
Gain unparalleled access to our growing industry data resources — a robust collection of third-party sources and our own proprietary research. Access global mRNA and next-generation RNA research, investments, and insights. From clinical to financial data, we will ensure you have the knowledge to track sector progress through our regular reports.
Through our partnerships with industry stakeholders, we’re committed to nurturing talent with resources dedicated to training and development. Equip your team with the skills needed to drive your organization forward.
AMM partners with investor groups and financial institutions — critical connections that can support your organization’s capacity to secure capital for R&D — and invites members to join focused investor events, attracting investment for your initiatives.